First Targeted Therapy for Exon 20 Insertions in NSCLC Wins FDA Accelerated Approval

(MedPage Today) -- The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.
The approval stipulates...